Salud Pública de México

Vaccines against papillomavirus infections and disease

Vaccines against papillomavirus infections and disease


Luisa Lina Villa, Ph D.(1)

(1) Ludwig Institute for Cancer Research, Sao Paulo, Brazil.


El cáncer de células escamosas del cérvix uterino es la segunda causa de muerte relacionada con cáncer en mujeres en el mundo; la incidencia más alta se ha observado en países en desarrollo. La infección con tipos oncogénicos de virus de papiloma humano es considerado el factor de riesgo principal para el desarrollo de malignidad en el cérvix uterino. Sin embargo, el virus es considerado una causa necesaria pero no suficiente para desarrollo de cáncer cervical y, por lo tanto, existen otros factores en el ambiente y en el huésped que contribuyen al proceso carcinogénico. Estudios desarrollados en animales, y más recientemente en humanos, indican que la vacunación en contra de la cápside de las proteínas del virus puede prevenir eficientemente la infección en forma profiláctica; además, las vacunas terapéuticas están bajo investigación con el propósito de promover regresión de los tumores inducidos por virus de papiloma humano. Las bases científicas de las vacunas desarrolladas contra este virus, y el estado actual de los ensayos clínicos que se desarrollan en el ámbito mundial, se presentan en este artículo.


Squamous cell carcinoma of the uterine cervix is the second cause of cancer-related deaths in women, the higher incidence being observed in developing countries. Infection with oncogenic types of human papillomavirus (HPV) is considered the major risk factor for the development of malignancies in the uterine cervix. However, HPV is considered to be a necessary but not sufficient cause for cervical cancer and, therefore, other factors contribute to the carcinogenic process, both present in the environment and from the host. Studies performed in animals, and more recently in humans, indicate that vaccination against the capsid proteins of the virus can prevent efficiently from infection. Furthermore, therapeutic vaccines are under investigation aiming the regression of papillomavirus induced tumors. The scientific basis for the development of papillomavirus vaccines and present status of clinical trials will be addressed in this chapter.


Papillomavirus biology and immune response

Papillomaviruses are epitheliotropic viruses present in the skin and mucosa of several animals. In humans, more than 100 types have been described. Mucosal and genital HPVs, consisting of about 30 types, are divided into low-risk (HPVs 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108) and high-risk (HPVs 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 68, 73, and 82), according to their presence in malignant lesions of the cervix.The latter types have been adequately evaluated as high risk types in relation to invasive cervical cancer. For all of them, risk estimates were greater than 30 (range 35-350) strongly suggesting that these associations are causal in nature.1,2

The genome of these viruses is a double stranded DNA molecule of about 8000 base pairs, with three identified regions: a late region (L) containing two genes -L1 and L2- which encode the viral capsid proteins; an early region (E) encoding for proteins involved in viral DNA replication and control of viral transcription, such as E1 and E2, as well as the main transforming genes E6, E7 and E5; a long control region (LCR), containing several binding sites for nuclear and viral transcriptional factors as well as promotor sequences, is found between the L and E regions. HPV genomes are found as episomes in the nucleus of infected cells of the normal cervix, where infective viral particles can be isolated. However, in some low-grade and in most of the high-grade lesions of the uterine cervix, including cancer, HPV genomes are found integrated into the host genome.3 A disruption of the E1-E2 region is required for HPV genome integration. This event results in an increased expression and stabilization of the E6 and E7 transcripts. The E6 protein from high-risk HPVs binds cellular p53, promoting the degradation of p53 by the cellular ubiquitin proteolysis system. The E7 protein interacts with pRB and inactivates this cellular protein. As a consequence, E2F transcription factor is released from pRB-E2F complex, leading to transcriptional activation of several genes involved in cell proliferation. Such interactions of HPV E6 and E7 proteins interfere with several pathways involved in the control of the cell cycle and DNA repair.4

Infection with high-risk HPV types is frequent among sexually active women, with incidence ranging from 15 to 40%.5 When additional cervical specimens are taken from these women in follow-up surveys, the majority of the infections are found to be transient. However, a small proportion of infected women has persistent infection with high-risk HPV types. Previous reports have demonstrated that women persistently infected with oncogenic HPV types are more likely to develop malignant cervical lesions. Persistence of HPV is due mostly to their ability to evade the immune system.6

Infections with HPV are accompanied by an immune response that is both humoral and cellular.7 Several studies have shown that serological diagnosis of HPV infection using genetically engineered HPV capsids (also known as Virus-Like Particles or VLP) correlate well with HPV DNA presence in cervical smears. The antibodies invoked recognize type-specific conformational epitopes present on VLPs, particularly against the viral capsid protein L1, and the humoral response (IgG) against HPVs is stable over time. Neutralizing antibodies are generated, although frequently in low titers, and are considered to be host protective against further infection with that virus type. Moreover, HPV VLP ELISAs show sensitivities between 50 and 60%, very high specificities (>90%) and show good interlaboratory agreement. Therefore, VLP serology has been used as a marker of cumulative exposure to HPV, and sexual behavior, despite the observation that seroconversion may be delayed or never occur in a subset of women testing positive for HPV DNA. Overall, frequency and titer of several types of antibodies generated against HPV show a great variability that is dependent on the HPV type specificity, on the recognized epitopes, on the type of samples, and sensitivity of the assay. The mere definition of cutoff values can hinder comparison between different epidemiological surveys. Despite the fact that integration of HPV genomes impairs the expression of capsid antigens, stronger positive associations have been described for tumors of the anogenital region when compared to seropositivity in patients with epithelial cancers in other anatomical locations, consistent with the HPV DNA evidence.8 Another source of misclassification could originate from different viral loads present in lesions or a differential immune response according to anatomical site. Concerning type specificity, it has been demonstrated that VLPs of each HPV type induce serum antibody response that are genotype-specific with the exception of HPV types 6 and 11 which are considered to be cross-reactive and HPV 31 and 45 who show low levels of cross-reactive antibodies against HPV 33 and 18, respectively.9,10 Likewise, variants of HPV 16 are considered to belong to the same serotype.11

Development of papillomavirus vaccines. Animal models

Since the early 1990s, several groups have succeeded in generating recombinant L1 only or L1 and L2 viruslike particles (VLPs) from any papillomavirus known,12 that resemble very closely the native virions but are devoided of the viral genome. VLPs produced in both prokaryotic (bacteria) and eukaryotic cells (yeast, insect, mammalian) reproduce the antigenicity of native virions by presenting conformational epitopes that have been shown to induce type specific virus neutralizing antibodies.12 Moreover, VLPs have been shown to bind directly to dendritic cells leading to their activation and ultimately a potent T and B cell immune responses.13,14 Although VLPs are the tes for immunogens, several other antigens, including structural and non-structural papillomavirus proteins have been tested in different protocols.15 In addition, HPV early proteins such as E7, E6 and E2 have been fused to VLPs.16,17 These chimeric VLP vaccines have been shown to induce neutralizing antibodies and to elicit CTL responses specific to the early viral protein in murine models, as mentioned below. Finally, recombinant virus, in different vectors, have been used as DNA vaccines, either alone or in combination with adjuvants.18

The animal models of papillomavirus infection have proved extremely valuable in the search and development of anti-viral vaccines both prophylactically and therapeutically,15,19,20 Immunization with purified species-specific VLPs induces neutralizing antibodies that protect against live virus challenge in rabbits, cows and dogs. Among these models, the mucosal infections caused by COPV (canine oral papillomavirus) 21 and ROPV (rabbit oral papillomavirus)22 are those that resemble more the human genital papillomavirus infections. Interestingly, in bovines, vaccines based on the same viral target can be effective either prophylactically or therapeutically, inducing regression of early lesions, thus challenging the concept that viral structural protein vaccines would provide protection from, and non-structural protein vaccines cure of, virus-induced lesions.19 The duration of protection is long lasting, at least in rabbits23,24 where neutralizing antibodies have been induced upon injection of CRPV VLPs. A COPV-VLP vaccine has been shown to efficiently prevent the development of mucosal lesions in dogs.25 In Rhesus macaques, vaccination with an HPV-16 L1 VLP vaccine induced strong humoral, including neutralizing antibodies, and cellular immune responses.26 Interestingly, a low level of neutralizing antibodies was generated when the vaccine was delivered as a DNA vaccine or by administration of an adenoviral vector expressing HPV 16 L1, indicating that the delivery system may interfere with the nature of the immune response. Non-human primates have also being used to test a chimeric VLP vaccine consisting of both HPV L1 proteins and fragments of proteins from Simian Immunodeficiency Virus (SIV) and Human Immunodeficiency Virus (HIV).27 Systemic and mucosal administration of these HPV-SHIV VLPs generated responses against HPV L1, very weak antibodies or T cells responses to SHIV VLPs were only observed in macaques that were DNA primed before receiving the HPV-SHIV vaccines.

Although no papillomavirus is known to infect the regular laboratory mice, experimental models are available based on mouse cell lines transformed with highrisk HPV capable of inducing tumors and metastasis. These models provide a mean to test the immune responses generated by different vaccination strategies and information is rapidly accumulating.18,28,29 Moreover, these animal models have been used to test for different adjuvants and administration regimens, showing variable efficacies. Combined immunotherapy strategies include the use of BCG linked to HPV 16 E7,30,31 as well as administration of allogeneic tumor cells expressing both the viral oncoproteins and granulocyte-macrophage colony-stimulating factor (GMCSF).32 This mouse model has been particularly useful in testing different administration routes: Intranasal and oral administration of HPV VLPs alone or in combination with different adjuvants has been shown to be immunogenic.33-35 Recently, HPV 16 L1 capsomeres, administered both sub-cutaneously and intranasally, have been show to induce a potent CTL response, comparable to that obtained with VLPs.36 Similar results have been previously described for COPV-induced lesions in dogs.37 Murine models have been instrumental to show that anti-specific HPV responses can be obtained by DNA immunization, which can both control tumor and metastasis development and promote tumor regression.38-41 DNA vaccines have also been tested in rabbits42,43 and dogs44 with similar results. Altogether, the encouraging results obtained with different animal models have warranted the development of HPV vaccines in humans.

Vaccines to prevent human papillomavirus infection

Vaccines to prevent HPV infection aim to induce neutralizing antibodies directed to conformational epitopes of capsid proteins which most probably will be type specific. The protection against infection depends on the amount of antibodies produced by the host, its availability at the infection site and the persistence of the neutralizing antibodies along time. Analogous to the studies conducted with animals, VLPs for the most prevalent HPV types have been generated and tested as vaccine candidates in several ongoing clinical trials. Most of these studies are randomized, placebo-controlled, blinded trials, that include young woman living in different countries around the World. So far, the published studies with prophylactic HPV vaccines in humans have shown that the vaccine is well-tolerated and generates strong immune responses that are several orders of magnitude higher than those exhibited by naturally infected populations. These safety and immunogenicity trials were done with VLPs against low-risk type 11 generated in insect cells45 or yeast,46 as well as with high-risk type 16 VLPs produced in insect cells47 or yeast.48 The interim analysis of one of the trials has been recently published showing that women injected with HPV type 16 virus-like particles (VLPs) have been protected against infection when compared to the placebo group.48 Moreover, during the 17-month period of follow-up, the few cases of cervical lesions attributed to this HPV type developed only in women that did not receive the vaccine. These results are very encouraging and constitute the proofof-principle of the feasibility of this monovalent HPV vaccine developed by Merck, Sharp and Dohme.

However, HPV-16 accounts for about 50% of all cervical cancers, and as mentioned earlier, the immune responses against HPV are type specific. Therefore, efforts are been made to develop multivalent vaccines that could control for most HPV infections associated with cervical disease namely HPV-18, -31, -33, -45, among other types. One of these studies is testing the safety and efficacy of a quadrivalent (HPV 6, 11, 16, 18) VLP vaccine. The study conducted in Brazil, USA, and several Nordic countries, followed more than 1 100 women for at least eight months.49 Preliminary data indicate that women who received the vaccine had significantly higher amounts of HPV neutralizing antibodies than women who developed the infection naturally. It has also confirmed that the vaccine is well tolerated. Other trials are being conducted in different countries around the World and should enroll thousands of young women in the next few years. They include several fase III protocols aiming to demonstrate this vaccine’s efficacy against HPV infections and cervical neoplasia. Although there are several questions to be answered, particularly concerning the efficacy and durability of the elicited immune response, it is reasonable to antecipate that the trials will succeed in demonstrating the value of VLP vaccines in the prophylaxis of HPV infections.

Therapeutic vaccines

New therapeutic approaches to cervical cancer include immunization with early proteins and derived peptides of high-risk HPV, aiming to eliminate epithelial cells in the anogenital tract that are already infected with papillomaviruses. One modality of treatment that might achieve this would be immunotherapy, either alone or in conjunction with specific antiviral drugs.50-52

Immune response to the E2 and E6 proteins may also predict the regression of papillomavirus-associated disease. Thus, targeting immunotherapy to some or all of the HPV early proteins, particularly E6 and E7, is being considered for treatment of papillomavirus-induced neoplasia.53,54 Immunogens include synthetic peptides, recombinant proteins, chimeric VLPs and live viral expression vectors. Pre-clinical studies indicate that these vaccines can eradicate HPV positive tumors.55,56

Although it has been possible to demonstrate that several papillomavirus early proteins are immunogenic in patients with HPV-associated cervical cancer, clinical trials of therapeutic vaccines have been conducted in patients with advanced stage of disease in whom a poor immune response is expected. Nevertheless, some positive results are available and partial responses have been obtained in patients with highgrade intraepithelial lesions.57,58 Promising results have been obtained in patients with genital warts.59,60 Clinical trials are underway to demonstrate the immunogenicity of a therapeutic DNA vaccine for anal dysplasia, consisting of an encapsulated plasmid bearing the sequences of HPV-16 E7 and multiple HLAA2-restricted epitopes.61 The potential use of dendritic cells expressing HPV antigens is under study.62-64

Final considerations

Despite the encouraging results from several ongoing vaccine trials showing good safety profiles and induction of high titers of virus specific antibody by VLP-based papillomavirus vaccines, there are several open issues that require attention. Even if a vaccine is shown to be effective against a few HPV types, it is not known how long the protection will last and what will be the impact of this type of prevention in the natural history of cervical cancer. It is expected that a multivalent HPV vaccine will reduce the number of interventions such as colposcopies, biopsies and treatment of precursor lesions. However, without full population coverage, Papanicolaou-based screening procedures, in conjunction with the recently approved HPV DNA test for primary screening of cervical cancer in the USA, are likely to continue to play an essential role. Furthermore, we do not know if effective coverage against some genotypes could favor the emergence of more pathogenic types. The implications for HPV evolution as a large and diverse family of viruses ought to be considered.65 Finally, the impact of various vaccination strategies in the prevention of cervical cancer, with a particular attention to its application in developing countries where an HPV vaccine is mostly needed, has been a matter of discussion in several recent articles.66-68 Concomitantly, there is much interest in the development of alternative papillomavirus vaccines, such as transgenic plants expressing papillomavirus proteins.69

Existence of tumor immune escape mechanisms puts therapeutic vaccines for HPV associated cancers in the same road as therapeutic vaccines for other cancers: so far, none have been shown to be completely effective. Development of multimodality treatments to induce strong immune responses and avoid escape from individual treatments are likely to contribute to the control of the precursors of cervical neoplasia of the uterine cervix and ultimately to invasive carcinoma.


1. Bosch FX, Lörincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.
2. Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsague X, Shah KV et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
3. zur Hausen H. Immortalization of human cells and their malignant conversion by high risk papillomavirus genotypes. Sem Cancer Biol 1999;9:405-411.
4. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89(2):213-228.
5. Bosch X. Epidemiology of human papillomavirus infections: New options for cervicakl prevention. Salud Publica Mex 2003;supl. 2:201-214.
6. Frazer IH, Thomas R, Zhou J, Leggatt GR, Dunn L, McMillan N et al. Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev 1999;168:131-142.
7. Konya J, Dillner J. Immunity to oncogenic human papillomaviruses. Advances Cancer Res 2001:205-238.
8. Strickler HD, Schiffman MH, Shah KV, Rabkin CS, Schiller JT, Wacholder S et al. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur J Cancer Prev 1998;7(4):305-313.
9. Combita AL, Bravo MM, Touzé AA, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 2002;97:796-803.
10. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck R et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001;19:1783-1793.
11. Pastrana D, Vass WC, Lowy DR, Schiller JT. NHPV 16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV 16. Virology 2001; 279:361-369.
12. Schiller JT, Roden RBS. Papillomavirus-like particles. Papillomavirus Rep 1995;6:121-128.
13. Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001;166(9):5346-5355.
14. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J
Immunol 2001;166(10):5917-5924.
15. Breitburd F, Coursaget P. Human papillomavirus vaccines. Semin Cancer Biol 1999;9(6):431-444.
16. Muller M, Zhou JA, Reed TD, Rittmuller C, Burger A, Gabelsberger J et al. Chimeric papillomavirus particles. Virology 1997;234:93-111.
17. Greenstone HL, Nieland JD, de Visser KE, de Bruijn MLH, Kirnbauer R, Roden RBS et al. Chimeric papillomavirus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumor model. Proc Natl Acad Sci 1998;95:1800-1805.
18. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998;5(4):231-252.
19. Campo MS. Animal models of papillomavirus pathogenesis. Virus Res 2002;89(2):249-261.
20. Schiller J, Lowy D. Papillomavirus-like particle based vaccines: Cervical cancer and beyond. Expert Opin Biol Ther 2001;1(4):571-581.
21. Nicholls PK, Klaunberg BA, Moore RA, Santos EB, Parry NR, Stanley MA. Naturally-occurring, non-regressing canine oral papillomavirus infection: Host immunity, virus characterisation and experimental infection. Virology 1999;265:365-374.
22. Peh WL, Middleton K, Christensen N, Nicholls P, Egawa K, Sotlar K et al. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol 2002;76(20):10401-10416.
23. Jansen KU, Rosolowsky M, Schultz L, Markus H, Cook JZ, Donnelly JJ et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits form CRPV-induced papilloma formation. Vaccine 1995;13:1509-1514.
24. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-965.
25. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-11557.
26. Tobery TW, Smith JF, Kuklin N, Skulsky D, Ackerson C, Huang L et al. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized Rhesus macaques. Vaccine 2003;21(13-14):1539-1547.
27. Dale CJ, Liu XS, De Rose R, Purcell DF, Anderson J, Xu Y et al. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques.Virology 2002;301(1):176-187.
28. Kast WM, Feltkamp MCW, Ressing ME, Vierboom MPM, Brandt RMP, Melief CJM. Cellular immunity against human papillomavirus associated cervical cancer. Sem Virol 1996;7:117-123.
29. Gerard CM, Baudson N, Kraemer K, Bruck C, Garcon N, Paterson Y et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 2001;19(17-19):2583-2589.
30. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guérin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000;121(2):216-225.
31. Jabbar IA, Fernando GJ, Saunders N, Aldovini A, Young R, Malcolm K et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000;18(22):2444-2453.
32. Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000;86(5):725-730.
33. Greer CE, Petracca R, Buonamassa DT, Di Tommaso A, Gervase B, Reeve RL et al. The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. Vaccine 2000;19(9-10):1008-1012.
34. Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 2001;279(1):354-360.
35. Gerber S, Lane C, Brown DM, Lord E, DiLorenzo M, Clements JD et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 2001;75(10):4752-4760.
36. Ohlschlager P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.J Virol 2003;77(8):4635-4645.
37. Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, Garcea RL et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 2001;75(17):7848-7853.
38. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999;6(12):1972-1981.
39. Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999;10(17):2727-2740.
40. Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001;281(2):231-238.
41. Rocha-Zavaleta L, Alejandre JE, García-Carrancá A. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 2002;66(1):86-95.
42. Schreckenberger C, Sethupathi P, Kanjanahaluethai A, Muller M, Zhou J, Gissmann L et al. Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. Vaccine 2000;19(2-3):227-233.
43. Leachman SA, Shylankevich M, Slade MD, Levine D, Sundaram RK, Xiao W et al. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 2002;76(15):7616-7624.
44. Perrin P, Jacob Y, Aguilar-Setien A, Loza-Rubio E, Jallet C, Desmezieres E et al. Immunization of dogs with a DNA vaccine induces protection against rabies virus.Vaccine 1999;1418(5-6):479-486.
45. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001;183(10):1485-1493.
46. Emeny RT, Wheeler CM, Jansen KU, Hunt WC, Fu TM, Smith JF et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 2002;76(15):7832-7842.
47. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93(4):284-292.
48. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine.N Engl J Med 2002;347(21):1645-1651.
49. Villa LL, Costa R, Petta C, Andrade R, Ault K, Giuliano A et al. A dose ranging safety and immunogenicity study of a quadrivalent hpv (types 6/11/16/18) L1 VLP vaccine in women. Abstract presented at the XX International Papillomavirus Conference, Paris 2002, October 4-9; Paris, France.
50. Frazer I. Vaccines for papillomavirus infection. Virus Res 2002;89(2):271-274.
51. Stanley MA. Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res 2002;89(2):241-248.
52. Berry JM, Palefsky JM. A review of human papillomavirus vaccines: From basic science to clinical trials. Front Biosci 2003;8:333-345.
53. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H et al. Clinical studies of human papilloma vaccines in cervical cancer. Adv Exp Med Biol 2001;495:419-427.
54. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000;23(2):255-266.
55. Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H et al. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 2001;92(2):285-293.
56. Zwaveling S, Ferreira-Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169(1):350-358.
57. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6(9):3406-3416.
58. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002;8(12):3676-3685.
59. Lacey CJ, Thompson HS, Monteiro EF, O’Neill T, Davies ML, Holding FP et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179(3):612-618.
60. Zhang LF, Zhou J, Chen S, Cai LL, Bao QY, Zheng FY et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000;18(11-12):1051-1058.
61. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002;8(5):1028-1037.
62. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998;15;58(4):724-731.
63. Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000;7(9):726-733.
64. Mendoza L, Bubenik J, Simova J, Jandlova T, Vonka V, Mikyskova R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol 2003;23(1):243-247.
65. Halpern AL. Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine. J Clin Virol 2000;19(1-2):43-56.
66. Goldie SJ. Health economics and cervical cancer prevention: A global perspective. Virus Res 2002;89(2):301-309.
67. Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res 2002;89(2):285-293.
68. Hughes JP, Garnett GP, Koustky L. The theoretical population-level impact of a prophylactic human papillomavirus vaccine. Epidemiology 2002;13(6):631-639.
69. Franconi R, Di Bonito P, Dibello F, Accardi L, Muller A, Cirilli A et al. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res 2002;62(13): 3654-3658.

Enlaces refback

  • No hay ningún enlace refback.

Salud Pública de México es una publicación periódica electrónica, bimestral, publicada por el Instituto Nacional de Salud Pública (con domicilio en Avenida Universidad núm. 655, col. Santa María Ahuacatitlán, Cuernavaca, Morelos, C.P. 62100, teléfono 329-3000, página web,, con ISSN: 1606-7916 y Reserva de Derechos al Uso Exclusivo con número: 04-2012-071614550600-203, ambos otorgados por el Instituto Nacional del Derecho de Autor. Editor responsable: Carlos Oropeza Abúndez. Responsable de la versión electrónica: Subdirección de Comunicación Científica y Publicaciones, Avenida Universidad núm. 655, planta baja, col. Santa María Ahuacatitlán, Cuernavaca, Morelos, C.P. 62100, teléfono 329 3000. Fecha de última modificación: 7 de junio de 2018. D.R. © por el sitio: Instituto Nacional de Salud Pública.

Gestionando el conocimiento